Blom I, Bäck O, Egelrud T, Frödin T, Hellbe L, Johannisson G, Malmros-Enander I, Molin L
Dermatologica. 1986;173(5):220-3. doi: 10.1159/000249257.
Thirty-three patients with frequently recurring genital herpes completed a randomized double-blind, crossover trial with oral acyclovir 200 mg 4 times a day and placebo for periods of 12 weeks. Five patients (15%) had full recurrence during acyclovir treatment and 31 (94%) while receiving placebo. The median time to first recurrence was 20 days for placebo and more than 84 days for acyclovir. It was concluded that acyclovir was well tolerated and an effective treatment to suppress the disease in selected cases of severe and frequently recurring genital herpes. However, the relapses seem to occur with the same rate as before, when the suppressive acyclovir treatment is stopped.
33例复发性生殖器疱疹患者完成了一项随机双盲交叉试验，他们每天口服4次200毫克阿昔洛韦，持续12周，另一阶段服用安慰剂。5例患者（15%）在阿昔洛韦治疗期间完全复发，31例患者（94%）在接受安慰剂治疗时复发。安慰剂组首次复发的中位时间为20天，阿昔洛韦组则超过84天。得出的结论是，阿昔洛韦耐受性良好，在治疗部分严重复发性生殖器疱疹病例中是一种有效的疾病抑制疗法。然而，当阿昔洛韦抑制性治疗停止后，复发率似乎与之前相同。
